SCHEDULE: Adage Capital Boosts Immunic Stake to 9.99%
Beneficial Ownership Report
Adage Capital Management, L.P. and its principals have reported a 9.99% beneficial ownership stake in Immunic, Inc., including shares from warrants.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 10,479,337 shares of Immunic, Inc. common stock.
- This ownership represents 9.99% of Immunic, Inc.'s outstanding common stock.
- The reported shares include 9,080,737 shares of common stock issuable upon the exercise of warrants.
- The percentage of class is calculated based on 95,817,536 shares of common stock outstanding as of May 14, 2025, as reported in the Company's Prospectus filed on May 30, 2025.
- The filing was made under Rule 13d-1(b), indicating the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor. The significant stake (9.99%) by a prominent firm like Adage Capital Management could be viewed positively by the market, suggesting investor confidence, but it does not inherently contain positive or negative news about the company's operations or financial performance.
Positives
- A significant stake by a reputable institutional investor like Adage Capital Management may signal confidence in Immunic, Inc.'s long-term prospects.
Negatives
- NA
Risks
- NA
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the company's future performance or operations.
Industry Context
The filing indicates a significant ownership position by a major investment firm in Immunic, Inc., a company operating in the biotechnology or pharmaceutical sector. Such an investment by a large fund like Adage Capital Management is a common occurrence in the industry, reflecting portfolio allocation decisions.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor holding a near 10% stake could be perceived positively, potentially increasing investor confidence and liquidity.
- Company Management: Awareness of a large, passive institutional holder may influence strategic decisions, though the filing states the shares are not held for control purposes.
Key Dates
| Date | Description |
|---|---|
| 2025-05-14 | Date as of which 95,817,536 shares of Common Stock were reported outstanding in the Company's Prospectus. |
| 2025-05-30 | Date the Company's Prospectus was filed pursuant to Rule 424(b)(5). |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-08-12 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Immunic Inc, Adage Capital Management, Beneficial Ownership, Institutional Investor, Common Stock, Warrants, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.